DOP020: Higher vedolizumab levels are associated with deep remission in patients with Crohn’s Disease and Ulcerative Colitis on maintenance therapy with vedolizumabECCO'17 Barcelona 2017
1
DOP021: Long-term effectiveness and safety of vedolizumab in patients with Crohn’s Disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension studyECCO'17 Barcelona 2017
1
DOP022: Vedolizumab (VDZ) and anti-α treatment effectiveness in patients with IBD treated in Germany: A retrospective chart reviewECCO'17 Barcelona 2017
1
DOP023: Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active Ulcerative Colitis: Results from the US VICTORY consortiumECCO'17 Barcelona 2017
1
DOP024: Vedolizumab clinical and post-marketing safety experience of opportunistic infectionsECCO'17 Barcelona 2017
1
DOP025: Efficacy of vedolizumab on extraintestinal manifestation in patients with Inflammatory Bowel Disease: A post-hoc analysis of the OBSERV-IBD cohort from the GETAIDECCO'17 Barcelona 2017
1
DOP026: Sustained remission with vedolizumab in patients with Moderately to Severely active Ulcerative Colitis: A GEMINI 1 post hoc analysis of Week 14 remittersECCO'17 Barcelona 2017
1
DOP027: Long-term efficacy and safety of ustekinumab in refractory Crohn’s Disease patients: A multicenter retrospective experienceECCO'17 Barcelona 2017
1
DOP028: Antibodies towards vedolizumab appear from week 2 onwards and disappear upon treatmentECCO'17 Barcelona 2017
1
DOP029: Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: Post-hoc analysis of the taxit trialECCO'17 Barcelona 2017
1
DOP030: Anti-TNF re-induction is as effective, simpler and cheaper compared with dose interval shortening following secondary loss of response in Crohn’s Disease: A dual centre ‘real world’ studyECCO'17 Barcelona 2017
1
DOP031: Subtherapeutic serum infliximab trough levels and complete mucosal healing are associated with sustained clinical remission after infliximab discontinuation in paediatric Crohn’s Disease patientsECCO'17 Barcelona 2017
1
DOP032: Hydrocortisone premedication withdrawal in patients on stable infliximab maintenance: Clinical and pharmacokinetic outcomesECCO'17 Barcelona 2017
1
DOP033: Severely active Ulcerative Colitis is associated with high baseline infliximab clearance, reduced serum half-life and worse endoscopic outcomesECCO'17 Barcelona 2017
1
DOP034: Serum adalimumab concentration 3 months after surgery is correlated with endoscopic recurrence in Crohn’s Disease patients treated with adalimumab for prevention of postoperative recurrenceECCO'17 Barcelona 2017
1
DOP035: High gammaglobulin and low albumin serum levels independently predict secondary loss of response to anti-TNFα therapy in IBDECCO'17 Barcelona 2017
1
DOP036: The therapeutic efficacy of anti-TNF requires Fc-gamma receptors and can be improved by antibody hypo-fucosylationECCO'17 Barcelona 2017
1
DOP037: A model for prediction of early surgery and complications in paediatric Crohn’s Disease; Results of the prospective GROWTH CD studyECCO'17 Barcelona 2017
1